Last reviewed · How we verify
Parnate (TRANYLCYPROMINE)
Parnate (generic name: TRANYLCYPROMINE) is a Monoamine Oxidase Inhibitor Small molecule drug developed by Advanz. It is currently FDA-approved (first approved 1961) for Major depressive disorder.
Parnate works by blocking an enzyme that breaks down certain neurotransmitters, allowing them to stay in the brain longer.
Parnate is a small molecule medication used to treat various conditions, including bleeding, hemorrhage, and AML, as well as perioperative bleeding in laminectomy. It is administered as tranexamic acid.
At a glance
| Generic name | TRANYLCYPROMINE |
|---|---|
| Sponsor | Advanz |
| Drug class | Monoamine Oxidase Inhibitor |
| Target | Amine oxidase [flavin-containing] B |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1961 |
Mechanism of action
The mechanism of action of tranylcypromine tablets as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).
Approved indications
- Major depressive disorder
Boxed warnings
- WARNING: SUICIDAL THOUGHTS AND BEHAVIORS and HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE WARNING: SUICIDAL THOUGHTS AND BEHAVIORS and HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE See full prescribing information for complete boxed warning. • Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. Tranylcypromine tablets are not approved for use in pediatric patients. ( 5.1 , 8.4 ) • Excessive consumption of foods or beverages with significant tyramine content or certain drugs can precipitate hypertensive crisis. Monitor blood pressure, allow for medication free intervals, and advise patients to avoid foods and beverages with high tyramine content. ( 5.2 , 7.1 , 7.2 ) Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . Tranylcypromine tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . Hypertensive Crisis with Significant Tyramine Use Excessive consumption of foods or beverages with significant tyramine content or the use of certain drugs with tranylcypromine tablets or after tranylcypromine tablets discontinuation can precipitate hypertensive crisis. Monitor blood pressure and allow for medication-free intervals between administration of tranylcypromine tablets and interacting drugs. Instruct patients to avoid ingestion of foods and beverages with high tyramine content [see Warnings and Precautions (5.2) and Drug Interactions (7.1 , 7.2) ] .
Common side effects
- Hepatitis
- Skin rash
- Alopecia
- Tinnitus
- Muscle spasm
- Tremors
- Myoclonic jerks
- Numbness
- Paresthesia
- Urinary retention
- Retarded ejaculation
- Anemia
Drug interactions
- Alpha/Beta Agonists
- Amphetamines
- CYP2A6 Substrates
- Indirectly Acting Sympathomimetic Amines
- Selective Serotonin Reuptake Inhibitors
- Serotonin/Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- almotriptan
- bupivacaine
- buspirone
- dextromethorphan
- eletriptan
Key clinical trials
- The Effect of Tranexamic Acid in Endoscopic and Microscopic Ear Surgery Cases on Surgeon Satisfaction (NA)
- Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery (PHASE4)
- Comparison of the Efficacy of Misoprostol and Tranexamic Acid for Postpartum Hemorrhage Prophylaxis in Cesarean Delivery
- Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
- MAO-B Occupancy in Depressed Patients (NA)
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Tranexamic Acid in Sleeve Gastrectomy (NA)
- Kaolin-based Hemostatic Gauze in Total Knee Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Parnate CI brief — competitive landscape report
- Parnate updates RSS · CI watch RSS
- Advanz portfolio CI
Frequently asked questions about Parnate
What is Parnate?
How does Parnate work?
What is Parnate used for?
Who makes Parnate?
What is the generic name of Parnate?
What drug class is Parnate in?
When was Parnate approved?
What development phase is Parnate in?
What are the side effects of Parnate?
What does Parnate target?
Related
- Drug class: All Monoamine Oxidase Inhibitor drugs
- Target: All drugs targeting Amine oxidase [flavin-containing] B
- Manufacturer: Advanz — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Major depressive disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing